0001651308-20-000008.txt : 20200121 0001651308-20-000008.hdr.sgml : 20200121 20200121165118 ACCESSION NUMBER: 0001651308-20-000008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200121 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200121 DATE AS OF CHANGE: 20200121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BeiGene, Ltd. CENTRAL INDEX KEY: 0001651308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981209416 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37686 FILM NUMBER: 20536838 BUSINESS ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 BUSINESS PHONE: 13459494123 MAIL ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 8-K 1 a8-kx21jan20.htm 8-K Document
false0001651308 0001651308 2020-01-21 2020-01-21


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): January 21, 2020

BEIGENE, LTD.
(Exact Name of Registrant as Specified in Charter)
Cayman Islands
001-37686
98-1209416
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands
(Address of Principal Executive Offices) (Zip Code)
+1 (345) 949-4123
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
 
BGNE
 
The NASDAQ Global Select Market
Ordinary Shares, par value $0.0001 per share*
 
06160
 
The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o







Item 8.01. Other Events.

On January 21, 2020, BeiGene, Ltd. (the “Company”) announced that the pivotal Phase 3 trial evaluating its anti-PD-1 antibody tislelizumab in combination with two chemotherapy regimens for the first-line treatment of patients with squamous non-small cell lung cancer (NSCLC), met the primary endpoint of improved progression-free survival (PFS) at the planned interim analysis, as assessed by independent review committee (IRC). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.
 
 
 
 
Exhibit No.
 
Description
99.1
 
Press release issued by the Company on January 21, 2020
 104
 
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL









Exhibit Index
 
 
 
 
Exhibit No.
 
Description
99.1
 
104
 
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
 

 








SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
BEIGENE, LTD.
 
 
 
Date: January 21, 2020
By: 
/s/ Scott A. Samuels        
 
Name:
Scott A. Samuels
 
Title:
Senior Vice President, General Counsel













 EX-99.1 2 a317-307readout_en.htm EXHIBIT 99.1 Exhibit

a317307readoutenimage1.jpg


BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
BEIJING, China, and CAMBRIDGE, MA, January 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the pivotal Phase 3 trial evaluating its anti-PD-1 antibody tislelizumab in combination with two chemotherapy regimens for the first-line treatment of patients with squamous non-small cell lung cancer (NSCLC), met the primary endpoint of improved progression-free survival (PFS) at the planned interim analysis, as assessed by independent review committee (IRC). In this study, patients with previously untreated advanced squamous NSCLC were randomized to receive either tislelizumab in combination with paclitaxel and carboplatin, tislelizumab in combination with nanoparticle albumin-bound (nab) paclitaxel (ABRAXANE®) and carboplatin, or paclitaxel and carboplatin alone. Based on the pre-planned interim analysis, both tislelizumab treatment arms crossed the pre-specified efficacy boundary compared to chemotherapy alone. The safety profile of tislelizumab in both combinations in this trial was consistent with the known risks of each study treatment, and no new safety signals were identified.
“Tislelizumab was recently approved in China for patients with relapsed or refractory classical Hodgkin’s lymphoma, and we have a broad development program with more than 5,000 patients enrolled in over 25 tislelizumab studies, including 15 potentially registration-enabling trials,” commented Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene. “We are extremely excited about the compelling results that tislelizumab demonstrated in this Phase 3 trial and for its potential use as a first-line treatment for patients in China with advanced squamous NSCLC. We look forward to continuing the development program for tislelizumab in lung cancer, which includes three other Phase 3 trials, and reporting additional data.”
The company plans to discuss its plans for filing a supplemental new drug application (sNDA) for tislelizumab as a first-line treatment for squamous NSCLC with the Center for Drug Evaluation (CDE) at the National Medical Products Administration (NMPA) in China and to present these data at an upcoming medical meeting.
This trial (NCT 03594747, known as BGB-A317-307) is a Phase 3, randomized, open-label, multi-center trial investigating tislelizumab combined with either paclitaxel and carboplatin or nab-paclitaxel (ABRAXANE, which is commercialized by BeiGene in China) and carboplatin compared with paclitaxel and carboplatin alone in patients with



a317307readoutenimage1.jpg


untreated stage IIIB or IV squamous NSCLC from mainland China, regardless of PD-L1 expression. The primary endpoint is PFS per IRC. Key secondary endpoints include overall survival and safety. The study began enrolling patients in July 2018, and 360 patients were randomized 1:1:1 to receive tislelizumab (200mg every three weeks) in combination with each of the chemotherapy regimens or chemotherapy only, until disease progression, unacceptable toxicity, physician decision or consent withdrawal. Patients on the chemotherapy-only control arm who experienced disease progression, verified by central independent review, were eligible to cross over to receive tislelizumab monotherapy.
“Squamous NSCLC remains a significant unmet need, representing approximately 30 percent of patients with NSCLC in China. This Phase 3 study was designed to assess the impact of tislelizumab given in combination with chemotherapy as a potential treatment to improve outcomes in patients with advanced squamous NSCLC, for whom prognoses are typically quite poor. These results give us hope that we could have a new treatment option for these patients,” commented Jie Wang, M.D., Professor at the Cancer Hospital Chinese Academy of Medical Sciences, in Beijing, China and lead investigator for the trial.
About Non-Small Cell Lung Cancer
In contrast to most Western countries where lung cancer death rates are decreasing, lung cancer incidence rate is still increasing in China.12 There were approximately 770,000 new cases of lung cancer in China in 2018 and it is the leading cause of cancer-related death in both men and women, with approximately 690,500 deaths in China in 2018.3 Non-small cell lung cancer (NSCLC) comprises the most common form of lung cancer in China.4 
About Tislelizumab
Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.
Tislelizumab is approved by the China National Medical Products Administration (NMPA) as a treatment for patients with classical Hodgkin’s lymphoma who received at



a317307readoutenimage1.jpg


least two prior therapies. A supplemental new drug application (sNDA) for tislelizumab in patients with previously treated locally advanced or metastatic urothelial carcinoma has been granted priority review by the Center for Drug Evaluation at the NMPA and is currently under review.
Tislelizumab is being studied in a broad clinical program as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, 15 potentially registration-enabling clinical trials are being conducted in China and globally, including 11 Phase 3 trials and four pivotal Phase 2 trials.
Tislelizumab is not approved for use outside of China.
About BeiGene
BeiGene is a global, commercial-stage research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 3,400 employees in the United States, China, Australia, and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. In the United States, BeiGene markets and distributes BRUKINSA™ (zanubrutinib) and in China, the Company has received approval to market its anti-PD-1 antibody tislelizumab and markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) under a license from Celgene Logistics Sarl, a Bristol-Myers Squibb company,5 and plans to market XGEVA® (denosumab) under a license from Amgen.6 For more information please visit www.beigene.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from the BGB-A317-307 Phase 3 trial of tislelizumab in patients with previously untreated advanced squamous NSCLC and other clinical trials of tislelizumab, the potential implications of clinical data for patients, BeiGene’s plans to discuss data from the BGB-A317-307 trial with the NMPA and present the data at an upcoming medical meeting, and BeiGene's advancement of, and anticipated clinical development, regulatory milestones and commercialization of tislelizumab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its



a317307readoutenimage1.jpg


drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene's limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
Investor Contact                Media Contact
Craig West                    Liza Heapes
+1 857-302-5189                + 1 857-302-5663
ir@beigene.com                 media@beigene.com
1 Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2 She J, Yang P, Hong Q, et al. Lung cancer in China: challenges and interventions. Chest 2013;143:1117-26.
3 Feng et al. Cancer Communications (2019) 39:22 https://doi.org/10.1186/s40880-019-0368-6
4 Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41.
5 ABRAXANE® is a registered trademark of Abraxis Bioscience LLC, a Bristol-Myers Squibb company; REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation, a Bristol-Myers Squibb company
6 XGEVA® is a registered trademark of Amgen



 EX-101.SCH 3 bgne-20200121.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 bgne-20200121_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 bgne-20200121_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 bgne-20200121_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Street Address Entity Address, Address Line One Entity Address, Street Address 2 Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of each class Title of 12(b) Security Trading Symbol Trading Symbol Name of each exchange on which registered Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 bgne-20200121_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 a317307readoutenimage1.jpg begin 644 a317307readoutenimage1.jpg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end JSON 9 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a8-kx21jan20.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "bgne-20200121_cal.xml" ] }, "definitionLink": { "local": [ "bgne-20200121_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "a8-kx21jan20.htm" ] }, "labelLink": { "local": [ "bgne-20200121_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bgne-20200121_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bgne-20200121.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bgne", "nsuri": "http://beigene.com/20200121", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8-kx21jan20.htm", "contextRef": "D2020Q1RDOT", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Document", "role": "http://beigene.com/role/CoverDocument", "shortName": "Cover Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8-kx21jan20.htm", "contextRef": "D2020Q1RDOT", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Street Address" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Street Address 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Document
Jan. 21, 2020
Cover page.  
Document Type 8-K
Document Period End Date Jan. 21, 2020
Entity Registrant Name BEIGENE, LTD.
Entity Incorporation, State or Country Code E9
Entity File Number 001-37686
Entity Tax Identification Number 98-1209416
Entity Address, Street Address c/o Mourant Governance Services (Cayman) Limited
Entity Address, Street Address 2 94 Solaris Avenue, Camana Bay
Entity Address, City or Town Grand Cayman
Entity Address, Postal Zip Code KY1-1108
Entity Address, Country KY
City Area Code 345
Local Phone Number 949-4123
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
Trading Symbol BGNE
Name of each exchange on which registered NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001651308
Amendment Flag false
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 97 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Document Sheet http://beigene.com/role/CoverDocument Cover Document Cover 1 false false All Reports Book All Reports a8-kx21jan20.htm a317-307readout_en.htm bgne-20200121.xsd bgne-20200121_cal.xml bgne-20200121_def.xml bgne-20200121_lab.xml bgne-20200121_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 15 0001651308-20-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001651308-20-000008-xbrl.zip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end XML 16 a8-kx21jan20_htm.xml IDEA: XBRL DOCUMENT 0001651308 2020-01-21 2020-01-21 false 0001651308 8-K 2020-01-21 BEIGENE, LTD. E9 001-37686 98-1209416 c/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 KY 345 949-4123 false false false false American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share BGNE NASDAQ false XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }